Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
2-CdA has activity in patients with relapsed or refractory CLL. However, patients who have received multiple prior regimens that included fludarabine are less likely to respond, and there can be significant morbidity. Treatment of patients with less prior therapy earlier in the natural history of the disease may lead to improved and more durable responses.